Quest Diagnostics Inc (DGX) 83.34 $DGX
Oxford Immunotec Announces Favorable Recommendation by the Magistrate Judge in Patent Infringement Litigation
Globe Newswire - Thu Sep 01, 6:17AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions, today announced that the U.S. Magistrate Judge in the Company's patent infringement lawsuit against Qiagen, Inc., Quest Diagnostics, Inc. and Laboratory Corporation of America Holdings has issued a recommendation denying in substantial part the defendants' motion to dismiss the Company's claims. In issuing his recommendation, the magistrate judge stated, "At this early juncture, the Court concludes that the in vitro aspect of the plaintiff's tuberculosis test is an 'inventive concept' because it improves on prior methods of detecting tuberculosis infection." The magistrate judge's recommendation should now allow the Company to press forward with its case against the three defendants, asserting infringement of its six patents relating to methods for diagnosing TB infection.
DGX: 83.34 (+0.30), OXFD: 10.59 (-0.02)
Downgrade Alert for Quest Diagnostics (DGX)
Comtex SmarTrend(R) - Thu Sep 01, 3:26AM CDT
Quest Diagnostics (NYSE
GX) was downgraded from Buy to Neutral at Mizuho today. The stock closed yesterday at $82.82 on volume of 1.6 million shares, above average daily volume of 906,000. Based on a current price of $82.82, Quest Diagnostics is currently 16.4% above its average consensus analyst price target of $69.21. The stock should find initial support at its 50-day moving average (MA) of $71.75 and further support at its 200-day MA of $68.54.
DGX: 83.34 (+0.30)
Quest Diagnostics Falls 1.36% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Aug 31, 1:58PM CDT
Quest Diagnostics (NYSE GX) traded in a range yesterday that spanned from a low of $81.65 to a high of $82.88. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $82.66 on volume of 823,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
DGX: 83.34 (+0.30)
After Yesterday's Decline of 1.36%, Quest Diagnostics Offers Investors Better Value
Comtex SmarTrend(R) - Wed Aug 31, 1:56PM CDT
Quest Diagnostics (NYSE GX) traded in a range yesterday that spanned from a low of $81.65 to a high of $82.88. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $82.66 on volume of 823,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
DGX: 83.34 (+0.30)
Quest Diagnostics' Sonora Quest Opens PSCs at Safeway
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:12AM CDT
Sonora Quest Laboratories of Quest Diagnostics (DGX), has recently opened six new Patient Service Centers (PSCs) at Safeway stores in Arizona.
USPH: 64.31 (+0.21), AFAM: 36.74 (+0.11), RDNT: 7.14 (+0.14), DGX: 83.34 (+0.30)
Research Reports Initiation on Medical Laboratories & Research Stocks -- Quest Diagnostics, Bruker, Organovo, and Alere
PR Newswire - Wed Aug 31, 7:00AM CDT
Stock-Callers.com draws investors' attention to these Medical Laboratories and Research equities: Quest Diagnostics Inc. (NYSE: DGX), Bruker Corp. (NASDAQ: BRKR), Organovo Holdings Inc. (NASDAQ: ONVO), and Alere Inc. (NYSE: ALR). Industry growth is influenced by a number of trends, which include demographics, emerging economies, biotech advances in genetics, and pathogen evolution. Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
ONVO: 3.94 (+0.07), DGX: 83.34 (+0.30), BRKR: 22.02 (-0.36), ALR: 40.07 (+0.94)
Sonora Quest Laboratories and Safeway Expand Highest-Quality Diagnostic Testing to Greater Arizona
PR Newswire - Mon Aug 29, 11:41AM CDT
Sonora Quest Laboratories and Safeway today announce the opening of six new Sonora Quest Laboratories Patient Service Centers (PSCs) located at Safeway stores statewide throughout Arizona. The new locations in Arizona are in addition to the two PSCs opened in November 2015.
DGX: 83.34 (+0.30)
FDA Advises Zika Test for All U.S. Blood: Will Hologic Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:37AM CDT
The recent FDA recommendation allowing Hologic???s (HOLX) Procleix assay to be one of the two tests to be used in the nationwide screening will boost its test revenue growth.
DGX: 83.34 (+0.30), IDXX: 113.95 (-0.14), HOLX: 38.50 (-0.01)
Quest Diagnostics Shares Up 27.7% Since SmarTrend's Buy Recommendation (DGX)
Comtex SmarTrend(R) - Thu Aug 25, 1:00AM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE GX) on February 18th, 2016 at $65.35. In approximately 6 months, Quest Diagnostics has returned 27.69% as of today's recent price of $83.45.
DGX: 83.34 (+0.30)
Quest Diagnostics: Strategic Initiatives & Tie-ups to Add Value
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 9:43AM CDT
On Aug 23, 2016, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
USPH: 64.31 (+0.21), AFAM: 36.74 (+0.11), RDNT: 7.14 (+0.14), DGX: 83.34 (+0.30)
Quest Diagnostics Approved to Use Electronic Drug Test Process for Federally-Mandated Workforce by U.S. Health and Human Services
PR Newswire - Thu Aug 18, 9:53AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic services, announced today that the U.S. Department of Health and Human Services (HHS) has authorized the company to perform drug testing using electronic Custody and Control Forms (eCCF) for federally-mandated, safety-sensitive workers. With the approval, Quest becomes the largest workplace drug testing provider certified to provide Federal eCCF, which can enhance efficiencies and improve the quality of the drug testing process, including collection and transport, by significantly reducing paper-based documentation.
DGX: 83.34 (+0.30)
Quest Diagnostics Shares Up 30.9% Since SmarTrend's Buy Recommendation (DGX)
Comtex SmarTrend(R) - Wed Aug 10, 12:54AM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE GX) on February 18th, 2016 at $65.35. In approximately 6 months, Quest Diagnostics has returned 30.85% as of today's recent price of $85.52.
DGX: 83.34 (+0.30)
Quest Diagnostics To Speak At The 18th Annual Pacific Crest Global Technology Leadership Forum
PR Newswire - Fri Aug 05, 9:59AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 18th Annual Pacific Crest Global Technology Leadership Forum in Vail, Colorado. Lidia Fonseca, the company's Senior Vice President and CIO, will discuss the company's technology solutions and the role of technology within the organization. The presentation is scheduled for Tuesday, August 9th, 2016 at 1:30 p.m. Eastern Time.
DGX: 83.34 (+0.30)
Quest Diagnostics To Speak At The Canaccord Genuity 36th Annual Growth Conference
PR Newswire - Fri Aug 05, 9:24AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Canaccord Genuity 36th Annual Growth Conference in Boston, Massachusetts. Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Wednesday, August 10, 2016 at 10:00 a.m. Eastern Time.
DGX: 83.34 (+0.30)
Quest Diagnostics Launches New Digital Dementia Assessment Test to Aid Physicians' Assessment of Individuals with Cognitive Dysfunction
PR Newswire - Thu Aug 04, 8:05AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced CogniSense(TM), a digital cognitive assessment tool that aids in a physician's assessment, diagnosis and care management of individuals with cognitive dysfunction. CogniSense is designed to overcome several limitations of conventional paper-based cognitive assessment, such as lack of objective, easily trackable data over time and integration to electronic health records (EHRs).
DGX: 83.34 (+0.30)
Quest Diagnostics and AncestryDNA Collaborate to Expand Consumer DNA Testing
PR Newswire - Wed Aug 03, 5:45AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and AncestryDNA, the leader in family history and consumer genomics, are teaming up to help meet the rapidly growing consumer demand for genetic tests that provide insights into genetic ethnicity, origins and other factors. The new collaboration will allow AncestryDNA to scale its testing services and pave the way for new wellness offerings.
DGX: 83.34 (+0.30)
Quest Diagnostics Up 30.0% Since SmarTrend Uptrend Call (DGX)
Comtex SmarTrend(R) - Tue Aug 02, 1:17PM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE GX) on February 18th, 2016 at $65.35. In approximately 6 months, Quest Diagnostics has returned 30.04% as of today's recent price of $84.99.
DGX: 83.34 (+0.30)
Data Diagnostics Healthcare Technology Wins Two Gold Honors for Innovation in the 2016 Golden Bridge Awards
PR Newswire - Wed Jul 27, 12:31PM CDT
Quest Diagnostics (NYSE: DGX) and Inovalon (NASDAQ: INOV) today announced that Data Diagnostics(TM), a point-of-care health analytics technology, has won two gold medals at the 2016 Golden Bridge Awards. The solution earned gold in the categories of New Product, Service, Upgrade, or Innovation of the Year and Innovations in Technology. The annual Golden Bridge Awards are an industry and peer recognition program honoring the world's best products, services and companies.
DGX: 83.34 (+0.30), INOV: 16.39 (+0.30)
Oxford Immunotec Announces Favorable Recommendation by the Magistrate Judge in Patent Infringement Litigation
Globe Newswire - Thu Sep 01, 6:17AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions, today announced that the U.S. Magistrate Judge in the Company's patent infringement lawsuit against Qiagen, Inc., Quest Diagnostics, Inc. and Laboratory Corporation of America Holdings has issued a recommendation denying in substantial part the defendants' motion to dismiss the Company's claims. In issuing his recommendation, the magistrate judge stated, "At this early juncture, the Court concludes that the in vitro aspect of the plaintiff's tuberculosis test is an 'inventive concept' because it improves on prior methods of detecting tuberculosis infection." The magistrate judge's recommendation should now allow the Company to press forward with its case against the three defendants, asserting infringement of its six patents relating to methods for diagnosing TB infection.
DGX: 83.34 (+0.30), OXFD: 10.59 (-0.02)
Downgrade Alert for Quest Diagnostics (DGX)
Comtex SmarTrend(R) - Thu Sep 01, 3:26AM CDT
Quest Diagnostics (NYSE
GX) was downgraded from Buy to Neutral at Mizuho today. The stock closed yesterday at $82.82 on volume of 1.6 million shares, above average daily volume of 906,000. Based on a current price of $82.82, Quest Diagnostics is currently 16.4% above its average consensus analyst price target of $69.21. The stock should find initial support at its 50-day moving average (MA) of $71.75 and further support at its 200-day MA of $68.54. DGX: 83.34 (+0.30)
Quest Diagnostics Falls 1.36% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Aug 31, 1:58PM CDT
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $81.65 to a high of $82.88. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $82.66 on volume of 823,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. DGX: 83.34 (+0.30)
After Yesterday's Decline of 1.36%, Quest Diagnostics Offers Investors Better Value
Comtex SmarTrend(R) - Wed Aug 31, 1:56PM CDT
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $81.65 to a high of $82.88. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $82.66 on volume of 823,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. DGX: 83.34 (+0.30)
Quest Diagnostics' Sonora Quest Opens PSCs at Safeway
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:12AM CDT
Sonora Quest Laboratories of Quest Diagnostics (DGX), has recently opened six new Patient Service Centers (PSCs) at Safeway stores in Arizona.
USPH: 64.31 (+0.21), AFAM: 36.74 (+0.11), RDNT: 7.14 (+0.14), DGX: 83.34 (+0.30)
Research Reports Initiation on Medical Laboratories & Research Stocks -- Quest Diagnostics, Bruker, Organovo, and Alere
PR Newswire - Wed Aug 31, 7:00AM CDT
Stock-Callers.com draws investors' attention to these Medical Laboratories and Research equities: Quest Diagnostics Inc. (NYSE: DGX), Bruker Corp. (NASDAQ: BRKR), Organovo Holdings Inc. (NASDAQ: ONVO), and Alere Inc. (NYSE: ALR). Industry growth is influenced by a number of trends, which include demographics, emerging economies, biotech advances in genetics, and pathogen evolution. Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
ONVO: 3.94 (+0.07), DGX: 83.34 (+0.30), BRKR: 22.02 (-0.36), ALR: 40.07 (+0.94)
Sonora Quest Laboratories and Safeway Expand Highest-Quality Diagnostic Testing to Greater Arizona
PR Newswire - Mon Aug 29, 11:41AM CDT
Sonora Quest Laboratories and Safeway today announce the opening of six new Sonora Quest Laboratories Patient Service Centers (PSCs) located at Safeway stores statewide throughout Arizona. The new locations in Arizona are in addition to the two PSCs opened in November 2015.
DGX: 83.34 (+0.30)
FDA Advises Zika Test for All U.S. Blood: Will Hologic Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:37AM CDT
The recent FDA recommendation allowing Hologic???s (HOLX) Procleix assay to be one of the two tests to be used in the nationwide screening will boost its test revenue growth.
DGX: 83.34 (+0.30), IDXX: 113.95 (-0.14), HOLX: 38.50 (-0.01)
Quest Diagnostics Shares Up 27.7% Since SmarTrend's Buy Recommendation (DGX)
Comtex SmarTrend(R) - Thu Aug 25, 1:00AM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE
GX) on February 18th, 2016 at $65.35. In approximately 6 months, Quest Diagnostics has returned 27.69% as of today's recent price of $83.45. DGX: 83.34 (+0.30)
Quest Diagnostics: Strategic Initiatives & Tie-ups to Add Value
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 9:43AM CDT
On Aug 23, 2016, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
USPH: 64.31 (+0.21), AFAM: 36.74 (+0.11), RDNT: 7.14 (+0.14), DGX: 83.34 (+0.30)
Quest Diagnostics Approved to Use Electronic Drug Test Process for Federally-Mandated Workforce by U.S. Health and Human Services
PR Newswire - Thu Aug 18, 9:53AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic services, announced today that the U.S. Department of Health and Human Services (HHS) has authorized the company to perform drug testing using electronic Custody and Control Forms (eCCF) for federally-mandated, safety-sensitive workers. With the approval, Quest becomes the largest workplace drug testing provider certified to provide Federal eCCF, which can enhance efficiencies and improve the quality of the drug testing process, including collection and transport, by significantly reducing paper-based documentation.
DGX: 83.34 (+0.30)
Quest Diagnostics Shares Up 30.9% Since SmarTrend's Buy Recommendation (DGX)
Comtex SmarTrend(R) - Wed Aug 10, 12:54AM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE
GX) on February 18th, 2016 at $65.35. In approximately 6 months, Quest Diagnostics has returned 30.85% as of today's recent price of $85.52. DGX: 83.34 (+0.30)
Quest Diagnostics To Speak At The 18th Annual Pacific Crest Global Technology Leadership Forum
PR Newswire - Fri Aug 05, 9:59AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 18th Annual Pacific Crest Global Technology Leadership Forum in Vail, Colorado. Lidia Fonseca, the company's Senior Vice President and CIO, will discuss the company's technology solutions and the role of technology within the organization. The presentation is scheduled for Tuesday, August 9th, 2016 at 1:30 p.m. Eastern Time.
DGX: 83.34 (+0.30)
Quest Diagnostics To Speak At The Canaccord Genuity 36th Annual Growth Conference
PR Newswire - Fri Aug 05, 9:24AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Canaccord Genuity 36th Annual Growth Conference in Boston, Massachusetts. Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Wednesday, August 10, 2016 at 10:00 a.m. Eastern Time.
DGX: 83.34 (+0.30)
Quest Diagnostics Launches New Digital Dementia Assessment Test to Aid Physicians' Assessment of Individuals with Cognitive Dysfunction
PR Newswire - Thu Aug 04, 8:05AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced CogniSense(TM), a digital cognitive assessment tool that aids in a physician's assessment, diagnosis and care management of individuals with cognitive dysfunction. CogniSense is designed to overcome several limitations of conventional paper-based cognitive assessment, such as lack of objective, easily trackable data over time and integration to electronic health records (EHRs).
DGX: 83.34 (+0.30)
Quest Diagnostics and AncestryDNA Collaborate to Expand Consumer DNA Testing
PR Newswire - Wed Aug 03, 5:45AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and AncestryDNA, the leader in family history and consumer genomics, are teaming up to help meet the rapidly growing consumer demand for genetic tests that provide insights into genetic ethnicity, origins and other factors. The new collaboration will allow AncestryDNA to scale its testing services and pave the way for new wellness offerings.
DGX: 83.34 (+0.30)
Quest Diagnostics Up 30.0% Since SmarTrend Uptrend Call (DGX)
Comtex SmarTrend(R) - Tue Aug 02, 1:17PM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE
GX) on February 18th, 2016 at $65.35. In approximately 6 months, Quest Diagnostics has returned 30.04% as of today's recent price of $84.99. DGX: 83.34 (+0.30)
Data Diagnostics Healthcare Technology Wins Two Gold Honors for Innovation in the 2016 Golden Bridge Awards
PR Newswire - Wed Jul 27, 12:31PM CDT
Quest Diagnostics (NYSE: DGX) and Inovalon (NASDAQ: INOV) today announced that Data Diagnostics(TM), a point-of-care health analytics technology, has won two gold medals at the 2016 Golden Bridge Awards. The solution earned gold in the categories of New Product, Service, Upgrade, or Innovation of the Year and Innovations in Technology. The annual Golden Bridge Awards are an industry and peer recognition program honoring the world's best products, services and companies.
DGX: 83.34 (+0.30), INOV: 16.39 (+0.30)
